; onclick=)
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/cobimetinib-uses-dosage-side-effects-interaction_245517.jpg?fit=800%2C600&ssl=1" class="aligncenter wp-post-image" alt="" decoding="async" srcset="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/cobimetinib-uses-dosage-side-effects-interaction_245517.jpg?w=800&ssl=1 800w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/cobimetinib-uses-dosage-side-effects-interaction_245517.jpg?resize=768%2C576&ssl=1 768w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/cobimetinib-uses-dosage-side-effects-interaction_245517.jpg?resize=360%2C270&ssl=1 360w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/cobimetinib-uses-dosage-side-effects-interaction_245517.jpg?resize=600%2C450&ssl=1 600w" sizes="(max-width: 800px) 100vw, 800px" data-attachment-id="255619" data-permalink="https://rxharun.com/rxharun/drug-a-z/cobimetinib/attachment/cobimetinib-uses-dosage-side-effects-interaction/" data-orig-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/cobimetinib-uses-dosage-side-effects-interaction_245517.jpg?fit=800%2C600&ssl=1" data-orig-size="800,600" data-comments-opened="0" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Cobimetinib – Uses, Dosage, Side Effects, Interaction" data-image-description="" data-image-caption="" data-medium-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/cobimetinib-uses-dosage-side-effects-interaction_245517.jpg?fit=800%2C600&ssl=1" data-large-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/cobimetinib-uses-dosage-side-effects-interaction_245517.jpg?fit=800%2C600&ssl=1" data-jpibfi-post-excerpt="" data-jpibfi-post-url="https://rxharun.com/rxharun/drug-a-z/cobimetinib/" data-jpibfi-post-title="Cobimetinib – Uses, Dosage, Side Effects, Interaction" data-jpibfi-src="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/cobimetinib-uses-dosage-side-effects-interaction_245517.jpg?fit=800%2C600&ssl=1">
Cobimetinib is an orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in the inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Cobimetinib is an antineoplastic agent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway used to treat unresectable or metastatic melanoma. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a B-RAF mutation, which has been found to be associated with many tumor types. A threonine–tyrosine kinase and a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors, MEK1 is required for the transmission of growth-promoting signals from numerous receptor tyrosine kinases.
Cobimetinib is a tyrosine kinase receptor inhibitor that is used in combination with vemurafenib as therapy for selected forms of advanced malignant melanoma. The combination of cobimetinib and vemurafenib is commonly associated with serum enzyme elevations during therapy and with rare instances of clinically apparent acute liver injury.
Cobimetinib is a member of the class of N-acylazetidines obtained by selective formal condensation of the carboxy group of 3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid with the secondary amino group from the azetidine ring of 3-[(2S)-piperidin-2-yl]azetidin-3-ol. An inhibitor of mitogen-activated protein kinase that is used (as its fumarate salt) in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma. It has a role as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor and an antineoplastic agent. It is a member of piperidines, an N-acylazetidine, a tertiary alcohol, an aromatic amine, a secondary amino compound, a difluorobenzene, and an organoiodine compound. It is a conjugate base of a cobimetinib(1+).
Cobimetinib fumarate is a fumarate salt prepared from cobimetinib by a reaction of one molecule of fumaric acid for every two molecules of cobimetinib. An inhibitor of mitogen-activated protein kinase that is used in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma. It has a role as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor and an antineoplastic agent. It is a fumarate salt and an organoammonium salt. It contains a cobimetinib(1+).
Mechanism of Action
MEK inhibitor Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in the inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Cobimetinib and vemurafenib target two different kinases in the RAS/RAF/MEK/ERK pathway. Cobimetinib is an orally active, potent, and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and a central component of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.
Cobimetinib is a reversible inhibitor of mitogen-activated protein kinase 1 (MAPK)/extracellular signal-regulated kinase 1 (MEK1) and MEK2. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a BRAF mutation, which has been found to be associated with many tumor types. A threonine–tyrosine kinase and a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors, MEK1 is required for the transmission of growth-promoting signals from numerous receptor tyrosine kinases. Cobimetinib is used in combination with vemurafenib because the clinical benefit of a BRAF inhibitor is limited by intrinsic and acquired resistance. Reactivation of the MAPK pathway is a major contributor to treatment failure in BRAF-mutant melanomas, approximately ~80% of melanoma tumors become BRAF-inhibitor resistant due to reactivation of MAPK signaling. BRAF-inhibitor-resistant tumor cells are sensitive to MEK inhibition, therefore cobimetinib and vemurafenib will result in dual inhibition of BRAF and its downstream target, MEK.
Indications
- For the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Cobimetinib is used in combination with vemurafenib, a BRAF inhibitor.
- Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
- Treatment of all conditions included in the category of malignant neoplasms (except hematopoietic and lymphoid tissue) with Ras, Raf or MEK pathway activation
- Histiocytic Neoplasm
- Metastatic Melanoma
- Unresectable Melanoma
Use in Cancer
Cobimetinib fumarate is approved to be used with vemurafenib to treat:
- Melanoma that cannot be removed by surgery or has spread to other parts of the body. It is used in patients whose cancer has a certain mutation in the BRAF gene.
Cobimetinib fumarate is also being studied in the treatment of other types of cancer.
Contraindications
- diabetic retinopathy, a type of damage to the eye from diabetes
- detachment of the retina of the eye
- a blockage of blood vessels in the retina of the eye
- chronic heart failure
- bleeding
- abnormal liver function tests
- pregnancy
- a patient who is producing milk and breastfeeding
- muscle pain or tenderness with increase creatine kinase
- retinal eye changes caused by high blood pressure
Dosage
Strengths: 20 mg
Melanoma – Metastatic
- 60 mg orally once a day for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity
- The presence of BRAF V600E or V600K mutation in tumor specimens should be confirmed with an FDA-approved test prior to therapy initiation; information on FDA-approved tests is available at http://www.fda.gov/CompanionDiagnostics.
Renal Dose Adjustments
- Mild (CrCl 60 to 89 mL/min) to moderate (CrCl 30 to 59 mL/min) renal impairment: No adjustment recommended.
- Severe (CrCl less than 30 mL/min) renal impairment or end-stage renal disease: Data not available
Liver Dose Adjustments
- Mild (Child-Pugh A), moderate (Child-Pugh B), or severe (Child-Pugh C) hepatic impairment: No adjustment in the starting dose is recommended.
Liver Laboratory Abnormalities and Hepatotoxicity Occur During Treatment:
First Occurrence Grade 4:
- Withhold treatment for up to 4 weeks.
- Resume at next lower dose if improved to Grade 0 or 1; permanently discontinue drug if not improved to Grade 0 or 1 within 4 weeks.
- Permanently discontinue the drug for recurrent Grade 4 abnormalities/hepatotoxicity.
- First Dose Reduction: 40 mg orally once a day
- Second Dose Reduction: 20 mg orally once a day
- Permanently discontinue the drug if the patient is unable to tolerate 20 mg orally once a day.
Dose Adjustments
MODERATE OR STRONG CYP450 3A INHIBITORS:
- Do not take moderate or strong CYP450 3A inhibitors while taking this drug.
- If concurrent short-term (14 days or less) use of moderate CYP450 3A inhibitors is unavoidable for patients who are taking this drug at 60 mg, reduce the dose of this drug to 20 mg. After discontinuation of a moderate CYP450 3A inhibitor, resume the previous dose of this drug at 60 mg.
- Use an alternative to a moderate or strong CYP450 3A inhibitor in patients who are taking a reduced dose of this drug (20 or 40 mg daily).
RECOMMENDED DOSE REDUCTIONS:
- First dose reduction: 40 mg orally once a day
- Second dose reduction: 20 mg orally once a day
- Permanently discontinue this drug if the patient is unable to tolerate 20 mg orally once a day.
DOSE MODIFICATIONS FOR ADVERSE REACTIONS:
PRIMARY MALIGNANCIES (cutaneous and non-cutaneous):
- No adjustment is recommended.
HEMORRHAGE:
- Grade 3: Withhold this drug for up to 4 weeks; if improved to Grade 0 or 1, resume at the next lower dose level; if not improved within 4 weeks, permanently discontinue therapy.
- Grade 4: Permanently discontinue therapy.
CARDIOMYOPATHY:
- Asymptomatic, absolute decrease in left ventricular ejection fraction (LVEF) from baseline of greater than 10% AND less than the institutional lower limit of normal (LLN): Withhold therapy for 2 weeks; repeat LVEF. Resume at next lower dose if LVEF at or above LLN AND absolute decrease from baseline LVEF 10% or less. Permanently discontinue therapy if LVEF is less than LLN OR an absolute decrease from baseline LVEF is more than 10%.
- Symptomatic LVEF decrease from baseline: Withhold therapy for up to 4 weeks; repeat LVEF. Resume at the next lower dose if symptoms resolve, LVEF at or above LLN, AND absolute decrease from baseline LVEF 10% or less. Permanently discontinue therapy if symptoms persist, LVEF is less than LLN, OR absolute decrease from baseline LVEF of more than 10%.
DERMATOLOGIC REACTIONS:
- Intolerable Grade 2 or Grade 3 or 4: Reduce dose or withhold therapy.
SEROUS RETINOPATHY OR RETINAL VEIN OCCLUSION:
- Serious retinopathy: Withhold therapy for up to 4 weeks; if improved resume at the next lower dose level; if not improved or symptoms recur at the lower dose within 4 weeks, permanently discontinue therapy.
- Retinal vein occlusion: Permanently discontinue therapy.
LIVER LABORATORY ABNORMALITIES AND HEPATOTOXICITY:
- First occurrence Grade 4: Withhold therapy for up to 4 weeks; if improved to Grade 0 or 1, resume at the next lower dose level; if not improved to Grade 0 or 1 within 4 weeks, permanently discontinue therapy.
- Recurrent Grade 4: Permanently discontinue therapy.
RHABDOMYOLYSIS AND CREATINE PHOSPHOKINASE (CPK) ELEVATIONS:
- Grade 4 CPK elevation/any CPK elevation and myalgia: Withhold therapy for up to 4 weeks; if improved to Grade 3 or lower, resume at the next lower dose level: if not improved within 4 weeks, permanently discontinue therapy.
PHOTOSENSITIVITY:
- Intolerable Grade 2 or Grade 3 or 4: Withhold therapy for up to 4 weeks; if improved to Grade 0 or 1, resume at the next lower dose level; if not improved within 4 weeks, permanently discontinue therapy.
OTHER:
- Intolerable Grade 2 adverse reactions: Withhold therapy for up to 4 weeks; if improved to Grade 0 or 1, resume at the next lower dose level; if not improved within 4 weeks, permanently discontinue therapy.
- Any Grade 3 adverse reactions: Withhold therapy for up to 4 weeks; if improved to Grade 0 or 1, resume at the next lower dose level; if not improved within 4 weeks, permanently discontinue therapy.
- First occurrence of any Grade 4 adverse reaction: Withhold therapy until adverse reaction improves to Grade 0 or 1; resume at the next lower dose level, OR permanently discontinue therapy.
- Recurrent Grade 4 adverse reaction: Permanently discontinue therapy.
Administration advice:
- This drug may be taken with or without food.
- If a dose is missed, it can be taken up to 12 hours prior to the next dose to maintain the once-daily regimen.
- In case of vomiting after administration of a dose, the patient should not take an additional dose on that day and therapy should be continued the following day.
Side Effects
The Most Common
- mouth ulcers
- hair loss
- diarrhea
- rash that covers a large area of your body, blisters, or peeling skin
- changes in skin appearance
- new wart
- skin sore or red bump that bleeds or does not heal
- change in size or color of a mole
- unusual bleeding or bruising
- tarry or black stools
- blood in the urine
- unusual vaginal bleeding
- headache
- dizziness
- rapid, irregular, or pounding heartbeat
- coughing or wheezing
- shortness of breath
- swelling of the face, arms, legs, ankles, or feet
- tiredness
- muscle pain or weakness
- change in vision, including seeing halos (blurred outline around objects)
- yellowing of the skin or eyes
- dark-colored (tea-colored) urine
- pain in upper right part of the stomach
- nausea
- vomiting
- loss of appetite
More Common
- vision changes, partial vision loss, seeing halos around lights;
- unexplained muscle pain, tenderness, or weakness (especially if you also have fever and dark-colored urine);
- easy bruising or bleeding (nosebleeds, bleeding gums);
- signs of bleeding inside the body–weakness, dizziness, headache, red or pink urine, bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds;
- signs of a heart problem–cough, wheezing, shortness of breath (even with mild exertion), chest pain, fast heartbeats, swelling in your feet or ankles;
- low levels of sodium in the body–headache, confusion, slurred speech, severe weakness, vomiting, loss of coordination, feeling unsteady;
- liver problems–nausea, upper stomach pain, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); or
- severe skin reaction–skin pain, itching, redness, bumps or pimples, thickened or wrinkled skin, skin rash that spreads and causes blistering and peeling.
- nausea, vomiting, diarrhea;
- fever;
- sunburn or increased sensitivity to sunlight;
- low sodium levels; or
- abnormal laboratory tests.
Rare
- acne-like skin rash
- hives
- increased blood pressure
- increased sensitivity to sunlight (e.g., sunburn, rash)
- new skin cancer (e.g., new skin sore, wart, or bump on the skin that bleeds or does not heal)
- signs of anemia (low red blood cells; e.g., dizziness, pale skin, unusual tiredness or weakness, shortness of breath)
- signs of clotting problems (e.g., unusual nosebleeds, bruising, blood in urine, coughing blood, bleeding gums, cuts that don’t stop bleeding)
- signs of dehydration (e.g., decreased urine, dry skin, dry and sticky mouth, sleepiness, dizziness, headache, thirst, confusion)
- signs of infection (symptoms may include fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness)
- signs of liver problems (e.g., nausea, vomiting, diarrhea, loss of appetite, weight loss, yellowing of the skin or whites of the eyes, dark urine, pale stools)
- signs of muscle damage (e.g., unexplained muscle pain, tenderness, or weakness, or brown or discoloured urine)
- swelling ankles or feet
- swelling, pain, and redness of the palms of the hands and soles of the feet
- symptoms of heart problems (e.g., persistent cough, wheezing, shortness of breath, tiredness)
- symptoms of high blood sugar (e.g., frequent urination, increased thirst, excessive eating, unexplained weight loss, poor wound healing, infections, fruity breath odour)
- symptoms of irregular heartbeat (e.g., fast heartbeat, weakness, tiredness, dizziness, lightheadedness, confusion, chest pain, trouble breathing)
- symptoms of lung inflammation (e.g., trouble breathing, cough, fever or chills)
- tender red bumps under the skin
- vision problems (e.g., blurred vision, halos, missing parts of vision)
- signs of a serious allergic reaction (e.g., abdominal cramps, difficulty breathing, nausea and vomiting, or swelling of the face and throat)
- signs of a severe skin reaction such as blistering, peeling, a rash covering a large area of the body, a rash that spreads quickly, or a rash combined with fever or discomfort
- signs of bleeding in the stomach (e.g., bloody, black, or tarry stools; spitting up of blood; vomiting blood or material that looks like coffee grounds)
Drug Interaction
| DRUG | INTERACTION |
|---|---|
| Abametapir | The serum concentration of Cobimetinib can be increased when it is combined with Abametapir. |
| Abatacept | The metabolism of Cobimetinib can be increased when combined with Abatacept. |
| Abemaciclib | The metabolism of Abemaciclib can be decreased when combined with Cobimetinib. |
| Abrocitinib | The serum concentration of Cobimetinib can be increased when it is combined with Abrocitinib. |
| Acalabrutinib | The metabolism of Cobimetinib can be decreased when combined with Acalabrutinib. |
| Acenocoumarol | The metabolism of Acenocoumarol can be decreased when combined with Cobimetinib. |
| Acetaminophen | The metabolism of Cobimetinib can be increased when combined with Acetaminophen. |
| Acetazolamide | The metabolism of Cobimetinib can be decreased when combined with Acetazolamide. |
| Adalimumab | The metabolism of Cobimetinib can be increased when combined with Adalimumab. |
| Afatinib | The serum concentration of Cobimetinib can be increased when it is combined with Afatinib. |
| Albendazole | The metabolism of Cobimetinib can be decreased when combined with Albendazole. |
| Aldesleukin | The metabolism of Cobimetinib can be decreased when combined with Aldesleukin. |
| Alectinib | The metabolism of Alectinib can be decreased when combined with Cobimetinib. |
| Alpelisib | The metabolism of Cobimetinib can be increased when combined with Alpelisib. |
| Ambrisentan | The serum concentration of Cobimetinib can be increased when it is combined with Ambrisentan. |
| Aminoglutethimide | The metabolism of Cobimetinib can be increased when combined with Aminoglutethimide. |
| Aminophylline | The metabolism of Aminophylline can be decreased when combined with Cobimetinib. |
| Amiodarone | The serum concentration of Cobimetinib can be increased when it is combined with Amiodarone. |
| Amobarbital | The metabolism of Cobimetinib can be increased when combined with Amobarbital. |
| Amprenavir | The serum concentration of Cobimetinib can be increased when it is combined with Amprenavir. |
| Anakinra | The metabolism of Cobimetinib can be increased when combined with Anakinra. |
| Apalutamide | The serum concentration of Cobimetinib can be decreased when it is combined with Apalutamide. |
| Apixaban | The serum concentration of Cobimetinib can be increased when it is combined with Apixaban. |
| Apremilast | The metabolism of Cobimetinib can be increased when combined with Apremilast. |
| Aprepitant | The metabolism of Cobimetinib can be decreased when combined with Aprepitant. |
| Armodafinil | The metabolism of Cobimetinib can be increased when combined with Armodafinil. |
| Arsenic trioxide | The serum concentration of Cobimetinib can be increased when it is combined with Arsenic trioxide. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Articaine. |
| Asciminib | The serum concentration of Cobimetinib can be increased when it is combined with Asciminib. |
| Astemizole | The metabolism of Cobimetinib can be decreased when combined with Astemizole. |
| Asunaprevir | The serum concentration of Cobimetinib can be increased when it is combined with Asunaprevir. |
| Atazanavir | The serum concentration of Cobimetinib can be increased when it is combined with Atazanavir. |
| Atogepant | The serum concentration of Atogepant can be increased when it is combined with Cobimetinib. |
| Atorvastatin | The excretion of Atorvastatin can be decreased when combined with Cobimetinib. |
| Avacopan | The metabolism of Cobimetinib can be decreased when combined with Avacopan. |
| Avanafil | The serum concentration of Avanafil can be increased when it is combined with Cobimetinib. |
| Avatrombopag | The serum concentration of Cobimetinib can be increased when it is combined with Avatrombopag. |
| Axitinib | The metabolism of Axitinib can be decreased when combined with Cobimetinib. |
| Azithromycin | The metabolism of Cobimetinib can be decreased when combined with Azithromycin. |
| Beclomethasone | The metabolism of Cobimetinib can be increased when combined with Beclomethasone dipropionate. |
| Belantamab | The serum concentration of Cobimetinib can be increased when it is combined with Belantamab mafodotin. |
| Belinostat | The serum concentration of Cobimetinib can be increased when it is combined with Belinostat. |
| Belumosudil | The serum concentration of Cobimetinib can be increased when it is combined with Belumosudil. |
| Belzutifan | The serum concentration of Cobimetinib can be decreased when it is combined with Belzutifan. |
| Bempedoic acid | The excretion of Bempedoic acid can be decreased when combined with Cobimetinib. |
| Bendamustine | The serum concentration of Bendamustine can be increased when it is combined with Cobimetinib. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Benzocaine. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Benzyl alcohol. |
| Berotralstat | The metabolism of Cobimetinib can be decreased when combined with Berotralstat. |
| Betamethasone | The metabolism of Cobimetinib can be increased when combined with Betamethasone. |
| Betamethasone | The metabolism of Cobimetinib can be increased when combined with Betamethasone phosphate. |
| Betrixaban | The serum concentration of Cobimetinib can be increased when it is combined with Betrixaban. |
| Bexarotene | The metabolism of Cobimetinib can be increased when combined with Bexarotene. |
| Bicalutamide | The metabolism of Cobimetinib can be decreased when combined with Bicalutamide. |
| Bifonazole | The metabolism of Cobimetinib can be decreased when combined with Bifonazole. |
| Bimekizumab | The metabolism of Cobimetinib can be increased when combined with Bimekizumab. |
| Binimetinib | The serum concentration of Binimetinib can be increased when it is combined with Cobimetinib. |
| Bisoprolol | The serum concentration of Cobimetinib can be increased when it is combined with Bisoprolol. |
| Boceprevir | The serum concentration of Cobimetinib can be increased when it is combined with Boceprevir. |
| Bortezomib | The metabolism of Bortezomib can be decreased when combined with Cobimetinib. |
| Bosentan | The metabolism of Cobimetinib can be increased when combined with Bosentan. |
| Bosutinib | The metabolism of Cobimetinib can be decreased when combined with Bosutinib. |
| Brentuximab vedotin | The metabolism of Cobimetinib can be decreased when combined with Brentuximab vedotin. |
| Brigatinib | The metabolism of Brigatinib can be decreased when combined with Cobimetinib. |
| Brincidofovir | The serum concentration of Brincidofovir can be increased when it is combined with Cobimetinib. |
| Budesonide | The metabolism of Cobimetinib can be increased when combined with Budesonide. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Bupivacaine. |
| Buprenorphine | The metabolism of Cobimetinib can be decreased when combined with Buprenorphine. |
| Busulfan | The metabolism of Busulfan can be decreased when combined with Cobimetinib. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Butacaine. |
| Butalbital | The metabolism of Cobimetinib can be increased when combined with Butalbital. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Butamben. |
| Cabazitaxel | The metabolism of Cabazitaxel can be decreased when combined with Cobimetinib. |
| Cabergoline | The metabolism of Cabergoline can be decreased when combined with Cobimetinib. |
| Calcitriol | The metabolism of Cobimetinib can be increased when combined with Calcitriol. |
| Canagliflozin | The serum concentration of Cobimetinib can be increased when it is combined with Canagliflozin. |
| Canakinumab | The metabolism of Cobimetinib can be increased when combined with Canakinumab. |
| Candicidin | The metabolism of Cobimetinib can be decreased when combined with Candicidin. |
| Cannabidiol | The metabolism of Cobimetinib can be decreased when combined with Cannabidiol. |
| Capmatinib | The serum concentration of Cobimetinib can be increased when it is combined with Capmatinib. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Capsaicin. |
| Carbamazepine | The serum concentration of Cobimetinib can be decreased when it is combined with Carbamazepine. |
| Carfilzomib | The serum concentration of Cobimetinib can be increased when it is combined with Carfilzomib. |
| Carvedilol | The serum concentration of Cobimetinib can be increased when it is combined with Carvedilol. |
| Caspofungin | The excretion of Caspofungin can be decreased when combined with Cobimetinib. |
| Cefradine | The metabolism of Cobimetinib can be increased when combined with Cefradine. |
| Cenobamate | The serum concentration of Cobimetinib can be decreased when it is combined with Cenobamate. |
| Cephalexin | The metabolism of Cobimetinib can be decreased when combined with Cephalexin. |
| Ceritinib | The metabolism of Cobimetinib can be decreased when combined with Ceritinib. |
| Cerivastatin | The metabolism of Cobimetinib can be increased when combined with Cerivastatin. |
| Certolizumab pegol | The metabolism of Cobimetinib can be increased when combined with Certolizumab pegol. |
| Chloramphenicol | The metabolism of Cobimetinib can be decreased when combined with Chloramphenicol. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Chloroprocaine. |
| Chlorpromazine | The metabolism of Cobimetinib can be increased when combined with Chlorpromazine. |
| Cholecystokinin | The excretion of Cholecystokinin can be decreased when combined with Cobimetinib. |
| Cholic Acid | The excretion of Cholic Acid can be decreased when combined with Cobimetinib. |
| Cimetidine | The metabolism of Cobimetinib can be decreased when combined with Cimetidine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Cinchocaine. |
| Ciprofloxacin | The metabolism of Cobimetinib can be decreased when combined with Ciprofloxacin. |
| Cisapride | The metabolism of Cobimetinib can be decreased when combined with Cisapride. |
| Citalopram | The metabolism of Cobimetinib can be decreased when combined with Citalopram. |
| Clarithromycin | The serum concentration of Cobimetinib can be increased when it is combined with Clarithromycin. |
| Clevidipine | The metabolism of Cobimetinib can be increased when combined with Clevidipine. |
| Clobazam | The metabolism of Cobimetinib can be increased when combined with Clobazam. |
| Clobetasol | The metabolism of Cobimetinib can be increased when combined with Clobetasol propionate. |
| Clofazimine | The serum concentration of Cobimetinib can be increased when it is combined with Clofazimine. |
| Clofibrate | The metabolism of Cobimetinib can be increased when combined with Clofibrate. |
| Clomifene | The serum concentration of Cobimetinib can be increased when it is combined with Clomifene. |
| Clomipramine | The metabolism of Clomipramine can be decreased when combined with Cobimetinib. |
| Clonidine | The metabolism of Clonidine can be decreased when combined with Cobimetinib. |
| Clozapine | The metabolism of Cobimetinib can be decreased when combined with Clozapine. |
| Cobicistat | The serum concentration of Cobimetinib can be increased when it is combined with Cobicistat. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Cocaine. |
| Colchicine | The serum concentration of Cobimetinib can be increased when it is combined with Colchicine. |
| Conivaptan | The serum concentration of Cobimetinib can be increased when it is combined with Conivaptan. |
| Conjugated | The excretion of Conjugated estrogens can be decreased when combined with Cobimetinib. |
| Copanlisib | The metabolism of Copanlisib can be decreased when combined with Cobimetinib. |
| Corticotropin | The metabolism of Cobimetinib can be increased when combined with Corticotropin. |
| Cortisone acetate | The metabolism of Cobimetinib can be increased when combined with Cortisone acetate. |
| Crizotinib | The metabolism of Cobimetinib can be decreased when combined with Crizotinib. |
| Curcumin | The serum concentration of Cobimetinib can be increased when it is combined with Curcumin. |
| Cyclophosphamide | The metabolism of Cobimetinib can be increased when combined with Cyclophosphamide. |
| Cyclosporine | The metabolism of Cobimetinib can be decreased when combined with Cyclosporine. |
| Cyproterone | The metabolism of Cobimetinib can be decreased when combined with Cyproterone acetate. |
| Dabigatran etexilate | The serum concentration of Cobimetinib can be increased when it is combined with Dabigatran etexilate. |
| Dabrafenib | The serum concentration of Cobimetinib can be decreased when it is combined with Dabrafenib. |
| Daclatasvir | The serum concentration of Cobimetinib can be increased when it is combined with Daclatasvir. |
| Dacomitinib | The serum concentration of Cobimetinib can be increased when it is combined with Dacomitinib. |
| Dactinomycin | The serum concentration of Cobimetinib can be increased when it is combined with Dactinomycin. |
| Dalfopristin | The metabolism of Cobimetinib can be decreased when combined with Dalfopristin. |
| Danazol | The metabolism of Cobimetinib can be decreased when combined with Danazol. |
| Daptomycin | The serum concentration of Cobimetinib can be increased when it is combined with Daptomycin. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cobimetinib. |
| Darolutamide | The serum concentration of Cobimetinib can be increased when it is combined with Darolutamide. |
| Darunavir | The serum concentration of Cobimetinib can be increased when it is combined with Darunavir. |
| Dasabuvir | The serum concentration of Cobimetinib can be increased when it is combined with Dasabuvir. |
| Dasatinib | The metabolism of Cobimetinib can be decreased when combined with Dasatinib. |
| Daunorubicin | The metabolism of Cobimetinib can be decreased when combined with Daunorubicin. |
| Deferasirox | The metabolism of Cobimetinib can be increased when combined with Deferasirox. |
| Deflazacort | The metabolism of Cobimetinib can be increased when combined with Deflazacort. |
| Delavirdine | The serum concentration of Cobimetinib can be increased when it is combined with Delavirdine. |
| Desipramine | The metabolism of Cobimetinib can be decreased when combined with Desipramine. |
| Desvenlafaxine | The metabolism of Cobimetinib can be decreased when combined with Desvenlafaxine. |
| Dexamethasone | The serum concentration of Cobimetinib can be decreased when it is combined with Dexamethasone. |
| Dexamethasone acetate | The serum concentration of Cobimetinib can be decreased when it is combined with Dexamethasone acetate. |
| Dextropropoxyphene | The metabolism of Cobimetinib can be decreased when combined with Dextropropoxyphene. |
| Dicloxacillin | The metabolism of Cobimetinib can be increased when combined with Dicloxacillin. |
| Diethylstilbestrol | The metabolism of Cobimetinib can be decreased when combined with Diethylstilbestrol. |
| Difluocortolone | The metabolism of Cobimetinib can be increased when combined with Difluocortolone. |
| Digitoxin | The metabolism of Digitoxin can be decreased when combined with Cobimetinib. |
| Digoxin | The serum concentration of Cobimetinib can be increased when it is combined with Digoxin. |
| Dihydroergocornine | The metabolism of Cobimetinib can be decreased when combined with Dihydroergocornine. |
| Dihydroergocristine | The metabolism of Cobimetinib can be decreased when combined with Dihydroergocristine. |
| Dihydroergotamine | The metabolism of Cobimetinib can be decreased when combined with Dihydroergotamine. |
| Diltiazem | The metabolism of Cobimetinib can be decreased when combined with Diltiazem. |
| Dimethyl sulfoxide | The metabolism of Cobimetinib can be decreased when combined with Dimethyl sulfoxide. |
| Diosmin | The serum concentration of Cobimetinib can be increased when it is combined with Diosmin. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Diphenhydramine. |
| Docetaxel | The metabolism of Cobimetinib can be decreased when combined with Docetaxel. |
| Dofetilide | The metabolism of Dofetilide can be decreased when combined with Cobimetinib. |
| Dolutegravir | The serum concentration of Cobimetinib can be increased when it is combined with Dolutegravir. |
| Doxazosin | The metabolism of Cobimetinib can be decreased when combined with Doxazosin. |
| Doxorubicin | The metabolism of Cobimetinib can be decreased when combined with Doxorubicin. |
| Dronedarone | The metabolism of Cobimetinib can be decreased when combined with Dronedarone. |
| Drospirenone | The metabolism of Cobimetinib can be decreased when combined with Drospirenone. |
| Duvelisib | The metabolism of Cobimetinib can be decreased when combined with Duvelisib. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Dyclonine. |
| Ebastine | The metabolism of Cobimetinib can be decreased when combined with Ebastine. |
| Echinacea | The metabolism of Cobimetinib can be increased when combined with Echinacea. |
| Econazole | The serum concentration of Cobimetinib can be increased when it is combined with Econazole. |
| Edoxaban | The serum concentration of Cobimetinib can be increased when it is combined with Edoxaban. |
| Efavirenz | The serum concentration of Cobimetinib can be increased when it is combined with Efavirenz. |
| Elagolix | The serum concentration of Cobimetinib can be increased when it is combined with Elagolix. |
| Elbasvir | The serum concentration of Cobimetinib can be increased when it is combined with Elbasvir. |
| Elexacaftor | The metabolism of Cobimetinib can be decreased when combined with Elexacaftor. |
| Eliglustat | The serum concentration of Cobimetinib can be increased when it is combined with Eliglustat. |
| Elvitegravir | The serum concentration of Cobimetinib can be increased when it is combined with Elvitegravir. |
| Emapalumab | The metabolism of Cobimetinib can be increased when combined with Emapalumab. |
| Enasidenib | The serum concentration of Cobimetinib can be increased when it is combined with Enasidenib. |
| Enfortumab vedotin | The serum concentration of Cobimetinib can be increased when it is combined with Enfortumab vedotin. |
| Entrectinib | The serum concentration of Cobimetinib can be increased when it is combined with Entrectinib. |
| Enzalutamide | The serum concentration of Cobimetinib can be decreased when it is combined with Enzalutamide. |
| Epinephrine | The metabolism of Cobimetinib can be decreased when combined with Epinephrine. |
| Erdafitinib | The serum concentration of Cobimetinib can be increased when it is combined with Erdafitinib. |
| Ergotamine | The serum concentration of Cobimetinib can be increased when it is combined with Ergotamine. |
| Erlotinib | The metabolism of Cobimetinib can be decreased when combined with Erlotinib. |
| Ertugliflozin | The serum concentration of Cobimetinib can be increased when it is combined with Ertugliflozin. |
| Erythromycin | The metabolism of Cobimetinib can be decreased when combined with Erythromycin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cobimetinib. |
| Esketamine | The metabolism of Cobimetinib can be increased when combined with Esketamine. |
| Eslicarbazepine | The metabolism of Cobimetinib can be increased when combined with Eslicarbazepine. |
| Eslicarbazepine acetate | The metabolism of Cobimetinib can be increased when combined with Eslicarbazepine acetate. |
| Estetrol | The metabolism of Cobimetinib can be decreased when combined with Estetrol. |
| Estradiol acetate | The metabolism of Cobimetinib can be increased when combined with Estradiol acetate. |
| Estradiol benzoate | The metabolism of Cobimetinib can be increased when combined with Estradiol benzoate. |
| Estradiol cypionate | The metabolism of Cobimetinib can be increased when combined with Estradiol cypionate. |
| Estradiol dienanthate | The metabolism of Cobimetinib can be increased when combined with Estradiol dienanthate. |
| Estradiol valerate | The metabolism of Cobimetinib can be increased when combined with Estradiol valerate. |
| Etanercept | The metabolism of Cobimetinib can be increased when combined with Etanercept. |
| Ethambutol | The metabolism of Cobimetinib can be decreased when combined with Ethambutol. |
| Ethanol | The metabolism of Cobimetinib can be increased when combined with Ethanol. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Etidocaine. |
| Etoposide | The metabolism of Etoposide can be decreased when combined with Cobimetinib. |
| Etoricoxib | The metabolism of Cobimetinib can be decreased when combined with Etoricoxib. |
| Etravirine | The metabolism of Cobimetinib can be increased when combined with Etravirine. |
| Everolimus | The serum concentration of Cobimetinib can be increased when it is combined with Everolimus. |
| Favipiravir | The serum concentration of Cobimetinib can be increased when it is combined with Favipiravir. |
| Fedratinib | The serum concentration of Cobimetinib can be increased when it is combined with Fedratinib. |
| Felbamate | The metabolism of Cobimetinib can be increased when combined with Felbamate. |
| Fenofibrate | The metabolism of Cobimetinib can be decreased when combined with Fenofibrate. |
| Fexinidazole | The metabolism of Cobimetinib can be decreased when combined with Fexinidazole. |
| Fexofenadine | The serum concentration of Cobimetinib can be increased when it is combined with Fexofenadine. |
| Filgotinib | The serum concentration of Cobimetinib can be increased when it is combined with Filgotinib. |
| Flibanserin | The serum concentration of Cobimetinib can be increased when it is combined with Flibanserin. |
| Flucloxacillin | The metabolism of Cobimetinib can be increased when combined with Flucloxacillin. |
| Fluconazole | The metabolism of Cobimetinib can be decreased when combined with Fluconazole. |
| Flunisolide | The metabolism of Cobimetinib can be increased when combined with Flunisolide. |
| Fluocinolone | The metabolism of Cobimetinib can be increased when combined with Fluocinolone acetonide. |
| Fluocinonide | The metabolism of Cobimetinib can be increased when combined with Fluocinonide. |
| Fluocortolone | The metabolism of Cobimetinib can be increased when combined with Fluocortolone. |
| Fluoxetine | The metabolism of Cobimetinib can be decreased when combined with Fluoxetine. |
| Fluticasone | The metabolism of Cobimetinib can be increased when combined with Fluticasone. |
| Fluticasone furoate | The metabolism of Cobimetinib can be increased when combined with Fluticasone furoate. |
| Fluticasone propionate | The metabolism of Cobimetinib can be decreased when combined with Fluticasone propionate. |
| Fluvastatin | The excretion of Fluvastatin can be decreased when combined with Cobimetinib. |
| Fluvoxamine | The metabolism of Cobimetinib can be decreased when combined with Fluvoxamine. |
| Formestane | The metabolism of Cobimetinib can be increased when combined with Formestane. |
| Fosamprenavir | The metabolism of Cobimetinib can be decreased when combined with Fosamprenavir. |
| Fosaprepitant | The metabolism of Cobimetinib can be increased when combined with Fosaprepitant. |
| Fosnetupitant | The metabolism of Cobimetinib can be decreased when combined with Fosnetupitant. |
| Fosphenytoin | The serum concentration of Cobimetinib can be decreased when it is combined with Fosphenytoin. |
| Fostamatinib | The metabolism of Cobimetinib can be decreased when combined with Fostamatinib. |
| Fostemsavir | The serum concentration of Cobimetinib can be increased when it is combined with Fostemsavir. |
| Fusidic acid | The metabolism of Cobimetinib can be decreased when combined with Fusidic acid. |
| Futibatinib | The serum concentration of Cobimetinib can be increased when it is combined with Futibatinib. |
| Gadoxetic acid | The excretion of Gadoxetic acid can be decreased when combined with Cobimetinib. |
| Gemcitabine | The serum concentration of Cobimetinib can be increased when it is combined with Gemcitabine. |
| Gilteritinib | The metabolism of Cobimetinib can be decreased when combined with Gilteritinib. |
| Ginkgo biloba | The metabolism of Cobimetinib can be decreased when combined with Ginkgo biloba. |
| Glasdegib | The serum concentration of Cobimetinib can be increased when it is combined with Glasdegib. |
| Glecaprevir | The serum concentration of Cobimetinib can be increased when it is combined with Glecaprevir. |
| Glyburide | The metabolism of Cobimetinib can be decreased when combined with Glyburide. |
| Glycerol | The metabolism of Cobimetinib can be increased when combined with Glycerol phenylbutyrate. |
| Golimumab | The metabolism of Cobimetinib can be increased when combined with Golimumab. |
| Grazoprevir | The serum concentration of Cobimetinib can be increased when it is combined with Grazoprevir. |
| Griseofulvin | The metabolism of Cobimetinib can be increased when combined with Griseofulvin. |
| Haloperidol | The metabolism of Cobimetinib can be decreased when combined with Haloperidol. |
| Hydralazine | The metabolism of Cobimetinib can be decreased when combined with Hydralazine. |
| Hydrocortamate | The metabolism of Cobimetinib can be increased when combined with Hydrocortamate. |
| Hydrocortisone | The metabolism of Cobimetinib can be increased when combined with Hydrocortisone. |
| Hydrocortisone | The metabolism of Cobimetinib can be increased when combined with Hydrocortisone acetate. |
| Hydrocortisone | The metabolism of Cobimetinib can be increased when combined with Hydrocortisone butyrate. |
| Hydrocortisone succinate | The metabolism of Cobimetinib can be increased when combined with Hydrocortisone succinate. |
| Idelalisib | The metabolism of Idelalisib can be decreased when combined with Cobimetinib. |
| Ifosfamide | The metabolism of Cobimetinib can be increased when combined with Ifosfamide. |
| Imatinib | The serum concentration of Cobimetinib can be increased when it is combined with Imatinib. |
| Imipramine | The serum concentration of Imipramine can be increased when it is combined with Cobimetinib. |
| Indacaterol | The serum concentration of Cobimetinib can be increased when it is combined with Indacaterol. |
| Indinavir | The serum concentration of Cobimetinib can be increased when it is combined with Indinavir. |
| Infigratinib | The metabolism of Cobimetinib can be decreased when combined with Infigratinib. |
| Infliximab | The metabolism of Cobimetinib can be increased when combined with Infliximab. |
| Inotuzumab | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Cobimetinib. |
| Irbesartan | The metabolism of Cobimetinib can be decreased when combined with Irbesartan. |
| Irinotecan | The metabolism of Irinotecan can be decreased when combined with Cobimetinib. |
| Isavuconazole | The metabolism of Cobimetinib can be decreased when combined with Isavuconazole. |
| Isavuconazonium | The metabolism of Cobimetinib can be decreased when combined with Isavuconazonium. |
| Isoniazid | The metabolism of Cobimetinib can be decreased when combined with Isoniazid. |
| Isradipine | The metabolism of Cobimetinib can be decreased when combined with Isradipine. |
| Istradefylline | The serum concentration of Cobimetinib can be increased when it is combined with Istradefylline. |
| Itraconazole | The serum concentration of Cobimetinib can be increased when it is combined with Itraconazole. |
| Ivacaftor | The serum concentration of Cobimetinib can be increased when it is combined with Ivacaftor. |
| Ivosidenib | The metabolism of Cobimetinib can be increased when combined with Ivosidenib. |
| Ixabepilone | The serum concentration of Cobimetinib can be increased when it is combined with Ixabepilone. |
| Ixazomib | The metabolism of Ixazomib can be decreased when combined with Cobimetinib. |
| Ketazolam | The metabolism of Cobimetinib can be decreased when combined with Ketazolam. |
| Ketoconazole | The serum concentration of Cobimetinib can be increased when it is combined with Ketoconazole. |
| Lacosamide | The metabolism of Cobimetinib can be decreased when combined with Lacosamide. |
| Lanreotide | The metabolism of Cobimetinib can be decreased when combined with Lanreotide. |
| Lapatinib | The serum concentration of Cobimetinib can be increased when it is combined with Lapatinib. |
| Larotrectinib | The serum concentration of Cobimetinib can be increased when it is combined with Larotrectinib. |
| Lasmiditan | The serum concentration of Cobimetinib can be increased when it is combined with Lasmiditan. |
| Ledipasvir | The serum concentration of Cobimetinib can be increased when it is combined with Ledipasvir. |
| Lefamulin | The serum concentration of Cobimetinib can be increased when it is combined with Lefamulin. |
| Lemborexant | The serum concentration of Cobimetinib can be increased when it is combined with Lemborexant. |
| Lenvatinib | The serum concentration of Cobimetinib can be increased when it is combined with Lenvatinib. |
| Lesinurad | The metabolism of Cobimetinib can be increased when combined with Lesinurad. |
| Letermovir | The metabolism of Cobimetinib can be decreased when combined with Letermovir. |
| Levacetylmethadol | The metabolism of Levacetylmethadol can be decreased when combined with Cobimetinib. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Levobupivacaine. |
| Levoketoconazole | The serum concentration of Cobimetinib can be increased when it is combined with Levoketoconazole. |
| Levosalbutamol | The excretion of Levosalbutamol can be decreased when combined with Cobimetinib. |
| Levothyroxine | The serum concentration of Cobimetinib can be decreased when it is combined with Levothyroxine. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Lidocaine. |
| Linagliptin | The metabolism of Cobimetinib can be decreased when combined with Linagliptin. |
| Liothyronine | The excretion of Liothyronine can be decreased when combined with Cobimetinib. |
| Liotrix | The excretion of Liotrix can be decreased when combined with Cobimetinib. |
| Lomitapide | The serum concentration of Cobimetinib can be increased when it is combined with Lomitapide. |
| Lonafarnib | The serum concentration of Cobimetinib can be increased when it is combined with Lonafarnib. |
| Loncastuximab | The serum concentration of Cobimetinib can be increased when it is combined with Loncastuximab tesirine. |
| Loperamide | The serum concentration of Cobimetinib can be increased when it is combined with Loperamide. |
| Lopinavir | The serum concentration of Cobimetinib can be increased when it is combined with Lopinavir. |
| Lorlatinib | The serum concentration of Cobimetinib can be decreased when it is combined with Lorlatinib. |
| Losartan | The metabolism of Cobimetinib can be decreased when combined with Losartan. |
| Lovastatin | The metabolism of Cobimetinib can be decreased when combined with Lovastatin. |
| Loxapine | The serum concentration of Cobimetinib can be increased when it is combined with Loxapine. |
| Lumacaftor | The serum concentration of Cobimetinib can be decreased when it is combined with Lumacaftor. |
| Lusutrombopag | The serum concentration of Cobimetinib can be increased when it is combined with Lusutrombopag. |
| Manidipine | The metabolism of Cobimetinib can be decreased when combined with Manidipine. |
| Mannitol | The serum concentration of Cobimetinib can be increased when it is combined with Mannitol. |
| Maribavir | The serum concentration of Cobimetinib can be increased when it is combined with Maribavir. |
| Mavacamten | The serum concentration of Cobimetinib can be decreased when it is combined with Mavacamten. |
| Medroxyprogesterone | The metabolism of Cobimetinib can be increased when combined with Medroxyprogesterone acetate. |
| Mefloquine | The serum concentration of Cobimetinib can be increased when it is combined with Mefloquine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Meloxicam. |
| Meperidine | The metabolism of Cobimetinib can be decreased when combined with Meperidine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Mepivacaine. |
| Meprednisone | The metabolism of Cobimetinib can be increased when combined with Meprednisone. |
| Methadone | The metabolism of Cobimetinib can be decreased when combined with Methadone. |
| Methimazole | The serum concentration of Cobimetinib can be increased when it is combined with Methimazole. |
| Methotrexate | The metabolism of Methotrexate can be decreased when combined with Cobimetinib. |
| Methoxy | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cobimetinib. |
| Methylene blue | The serum concentration of Cobimetinib can be increased when it is combined with Methylene blue. |
| Methylergometrine | The metabolism of Cobimetinib can be decreased when combined with Methylergometrine. |
| Methylphenobarbital | The metabolism of Cobimetinib can be increased when combined with Methylphenobarbital. |
| Methylprednisolone | The metabolism of Cobimetinib can be increased when combined with Methylprednisolone. |
| Methylprednisone | The metabolism of Cobimetinib can be decreased when combined with Methylprednisone. |
| Methysergide | The metabolism of Cobimetinib can be decreased when combined with Methysergide. |
| Metreleptin | The metabolism of Cobimetinib can be increased when combined with Metreleptin. |
| Metronidazole | The metabolism of Cobimetinib can be decreased when combined with Metronidazole. |
| Metyrapone | The metabolism of Cobimetinib can be increased when combined with Metyrapone. |
| Miconazole | The metabolism of Cobimetinib can be decreased when combined with Miconazole. |
| Midazolam | The metabolism of Cobimetinib can be decreased when combined with Midazolam. |
| Midostaurin | The serum concentration of Cobimetinib can be increased when it is combined with Midostaurin. |
| Mifepristone | The serum concentration of Cobimetinib can be decreased when it is combined with Mifepristone. |
| Milnacipran | The metabolism of Cobimetinib can be decreased when combined with Milnacipran. |
| Miocamycin | The metabolism of Cobimetinib can be decreased when combined with Miocamycin. |
| Mirabegron | The serum concentration of Cobimetinib can be increased when it is combined with Mirabegron. |
| Mirtazapine | The metabolism of Cobimetinib can be decreased when combined with Mirtazapine. |
| Mitapivat | The metabolism of Cobimetinib can be increased when combined with Mitapivat. |
| Mitotane | The serum concentration of Cobimetinib can be decreased when it is combined with Mitotane. |
| Mobocertinib | The serum concentration of Cobimetinib can be decreased when it is combined with Mobocertinib. |
| Modafinil | The metabolism of Cobimetinib can be increased when combined with Modafinil. |
| Mometasone furoate | The metabolism of Cobimetinib can be increased when combined with Mometasone furoate. |
| Morphine | The serum concentration of Cobimetinib can be increased when it is combined with Morphine. |
| Mosunetuzumab | The metabolism of Cobimetinib can be decreased when combined with Mosunetuzumab. |
| Mycophenolate mofetil | The excretion of Mycophenolate mofetil can be decreased when combined with Cobimetinib. |
| Nafcillin | The metabolism of Cobimetinib can be increased when combined with Nafcillin. |
| Naloxone | The serum concentration of Cobimetinib can be increased when it is combined with Naloxone. |
| Nefazodone | The serum concentration of Cobimetinib can be increased when it is combined with Nefazodone. |
| Nelfinavir | The serum concentration of Cobimetinib can be increased when it is combined with Nelfinavir. |
| Neratinib | The serum concentration of Cobimetinib can be increased when it is combined with Neratinib. |
| Netupitant | The metabolism of Cobimetinib can be decreased when combined with Netupitant. |
| Niacin | The metabolism of Cobimetinib can be decreased when combined with Niacin. |
| Nicardipine | The metabolism of Cobimetinib can be decreased when combined with Nicardipine. |
| Nilotinib | The serum concentration of Cobimetinib can be increased when it is combined with Nilotinib. |
| Nilvadipine | The metabolism of Cobimetinib can be decreased when combined with Nilvadipine. |
| Nintedanib | The metabolism of Cobimetinib can be decreased when combined with Nintedanib. |
| Norethisterone | The metabolism of Cobimetinib can be decreased when combined with Norethisterone. |
| Norgestimate | The serum concentration of Cobimetinib can be increased when it is combined with Norgestimate. |
| Nortriptyline | The metabolism of Nortriptyline can be decreased when combined with Cobimetinib. |
| Noscapine | The metabolism of Cobimetinib can be decreased when combined with Noscapine. |
| Octreotide | The serum concentration of Cobimetinib can be increased when it is combined with Octreotide. |
| Olaparib | The metabolism of Cobimetinib can be decreased when combined with Olaparib. |
| Omadacycline | The serum concentration of Cobimetinib can be increased when it is combined with Omadacycline. |
| Ombitasvir | The serum concentration of Cobimetinib can be increased when it is combined with Ombitasvir. |
| Omeprazole | The metabolism of Cobimetinib can be increased when combined with Omeprazole. |
| Oritavancin | The metabolism of Cobimetinib can be increased when combined with Oritavancin. |
| Orphenadrine | The metabolism of Cobimetinib can be decreased when combined with Orphenadrine. |
| Osilodrostat | The metabolism of Cobimetinib can be decreased when combined with Osilodrostat. |
| Osimertinib | The metabolism of Osimertinib can be decreased when combined with Cobimetinib. |
| Ouabain | The excretion of Ouabain can be decreased when combined with Cobimetinib. |
| Oxcarbazepine | The metabolism of Cobimetinib can be increased when combined with Oxcarbazepine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Oxetacaine. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Oxybuprocaine. |
| Oxybutynin | The metabolism of Cobimetinib can be decreased when combined with Oxybutynin. |
| Paclitaxel | The metabolism of Cobimetinib can be increased when combined with Paclitaxel. |
| Pacritinib | The serum concentration of Cobimetinib can be increased when it is combined with Pacritinib. |
| Palbociclib | The serum concentration of Cobimetinib can be increased when it is combined with Palbociclib. |
| Paliperidone | The serum concentration of Cobimetinib can be increased when it is combined with Paliperidone. |
| Panobinostat | The metabolism of Panobinostat can be decreased when combined with Cobimetinib. |
| Paritaprevir | The serum concentration of Cobimetinib can be increased when it is combined with Paritaprevir. |
| Pasireotide | The metabolism of Cobimetinib can be decreased when combined with Pasireotide. |
| Pazopanib | The metabolism of Cobimetinib can be decreased when combined with Pazopanib. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Cobimetinib. |
| Pentobarbital | The serum concentration of Cobimetinib can be decreased when it is combined with Pentobarbital. |
| Perampanel | The metabolism of Cobimetinib can be increased when combined with Perampanel. |
| Pexidartinib | The metabolism of Pexidartinib can be decreased when combined with Cobimetinib. |
| Phenobarbital | The serum concentration of Cobimetinib can be decreased when it is combined with Phenobarbital. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Phenol. |
| Phenprocoumon | The metabolism of Phenprocoumon can be decreased when combined with Cobimetinib. |
| Phenylbutazone | The metabolism of Cobimetinib can be increased when combined with Phenylbutazone. |
| Phenytoin | The serum concentration of Cobimetinib can be decreased when it is combined with Phenytoin. |
| Pibrentasvir | The serum concentration of Cobimetinib can be increased when it is combined with Pibrentasvir. |
| Pimavanserin | The metabolism of Cobimetinib can be decreased when combined with Pimavanserin. |
| Pimozide | The metabolism of Cobimetinib can be decreased when combined with Pimozide. |
| Piperaquine | The metabolism of Cobimetinib can be decreased when combined with Piperaquine. |
| Pitavastatin | The excretion of Pitavastatin can be decreased when combined with Cobimetinib. |
| Pitolisant | The serum concentration of Cobimetinib can be decreased when it is combined with Pitolisant. |
| Pomalidomide | The metabolism of Pomalidomide can be decreased when combined with Cobimetinib. |
| Ponatinib | The serum concentration of Cobimetinib can be increased when it is combined with Ponatinib. |
| Posaconazole | The serum concentration of Cobimetinib can be increased when it is combined with Posaconazole. |
| Pralsetinib | The serum concentration of Cobimetinib can be increased when it is combined with Pralsetinib. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Pramocaine. |
| Pravastatin | The serum concentration of Cobimetinib can be increased when it is combined with Pravastatin. |
| Prednisolone | The metabolism of Cobimetinib can be increased when combined with Prednisolone. |
| Prednisolone | The metabolism of Cobimetinib can be increased when combined with Prednisolone acetate. |
| Prednisolone | The serum concentration of Cobimetinib can be decreased when it is combined with Prednisolone phosphate. |
| Prednisone | The metabolism of Cobimetinib can be increased when combined with Prednisone acetate. |
| Pretomanid | The metabolism of Cobimetinib can be decreased when combined with Pretomanid. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Prilocaine. |
| Primaquine | The metabolism of Cobimetinib can be decreased when combined with Primaquine. |
| Primidone | The serum concentration of Cobimetinib can be decreased when it is combined with Primidone. |
| Probenecid | The metabolism of Cobimetinib can be increased when combined with Probenecid. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Procaine. |
| Propafenone | The serum concentration of Cobimetinib can be increased when it is combined with Propafenone. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Proparacaine. |
| Propofol | The metabolism of Cobimetinib can be decreased when combined with Propofol. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Propoxycaine. |
| Quinidine | The serum concentration of Cobimetinib can be increased when it is combined with Quinidine. |
| Quinine | The serum concentration of Cobimetinib can be increased when it is combined with Quinine. |
| Quinupristin | The metabolism of Cobimetinib can be decreased when combined with Quinupristin. |
| Raloxifene | The metabolism of Cobimetinib can be decreased when combined with Raloxifene. |
| Ranolazine | The serum concentration of Cobimetinib can be increased when it is combined with Ranolazine. |
| Regorafenib | The serum concentration of Cobimetinib can be increased when it is combined with Regorafenib. |
| Relugolix | The serum concentration of Cobimetinib can be increased when it is combined with Relugolix. |
| Remdesivir | The metabolism of Cobimetinib can be decreased when combined with Remdesivir. |
| Reserpine | The serum concentration of Cobimetinib can be increased when it is combined with Reserpine. |
| Revefenacin | Cobimetinib may decrease the excretion rate of Revefenacin which could result in a higher serum level. |
| Ribociclib | The serum concentration of Cobimetinib can be increased when it is combined with Ribociclib. |
| Rifabutin | The metabolism of Cobimetinib can be increased when combined with Rifabutin. |
| Rifampicin | The serum concentration of Cobimetinib can be decreased when it is combined with Rifampicin. |
| Rifamycin | The serum concentration of Cobimetinib can be decreased when it is combined with Rifamycin. |
| Rifapentine | The serum concentration of Cobimetinib can be decreased when it is combined with Rifapentine. |
| Rilonacept | The metabolism of Cobimetinib can be increased when combined with Rilonacept. |
| Rilpivirine | The metabolism of Cobimetinib can be decreased when combined with Rilpivirine. |
| Rimegepant | The serum concentration of Cobimetinib can be increased when it is combined with Rimegepant. |
| Rimexolone | The serum concentration of Cobimetinib can be decreased when it is combined with Rimexolone. |
| Riociguat | The serum concentration of Cobimetinib can be increased when it is combined with Riociguat. |
| Ripretinib | The serum concentration of Cobimetinib can be increased when it is combined with Ripretinib. |
| Ritonavir | The serum concentration of Cobimetinib can be increased when it is combined with Ritonavir. |
| Rivaroxaban | The serum concentration of Cobimetinib can be increased when it is combined with Rivaroxaban. |
| Rofecoxib | The metabolism of Cobimetinib can be increased when combined with Rofecoxib. |
| Roflumilast | The metabolism of Cobimetinib can be decreased when combined with Roflumilast. |
| Rolapitant | The serum concentration of Cobimetinib can be increased when it is combined with Rolapitant. |
| Romidepsin | The metabolism of Romidepsin can be decreased when combined with Cobimetinib. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Ropivacaine. |
| Rosuvastatin | The metabolism of Cobimetinib can be decreased when combined with Rosuvastatin. |
| Roxithromycin | The metabolism of Cobimetinib can be decreased when combined with Roxithromycin. |
| Rucaparib | The metabolism of Cobimetinib can be decreased when combined with Rucaparib. |
| Rufinamide | The metabolism of Cobimetinib can be increased when combined with Rufinamide. |
| Ruxolitinib | The metabolism of Ruxolitinib can be decreased when combined with Cobimetinib. |
| Sapropterin | The serum concentration of Cobimetinib can be increased when it is combined with Sapropterin. |
| Saquinavir | The serum concentration of Cobimetinib can be increased when it is combined with Saquinavir. |
| Sarecycline | The serum concentration of Cobimetinib can be increased when it is combined with Sarecycline. |
| Sarilumab | The metabolism of Cobimetinib can be increased when combined with Sarilumab. |
| Satralizumab | The serum concentration of Cobimetinib can be decreased when it is combined with Satralizumab. |
| Secobarbital | The metabolism of Cobimetinib can be increased when combined with Secobarbital. |
| Secukinumab | The metabolism of Cobimetinib can be increased when combined with Secukinumab. |
| Selexipag | The serum concentration of Cobimetinib can be increased when it is combined with Selexipag. |
| Selumetinib | The serum concentration of Cobimetinib can be increased when it is combined with Selumetinib. |
| Sildenafil | The serum concentration of Cobimetinib can be increased when it is combined with Sildenafil. |
| Silodosin | The serum concentration of Cobimetinib can be increased when it is combined with Silodosin. |
| Siltuximab | The metabolism of Cobimetinib can be increased when combined with Siltuximab. |
| Simeprevir | The metabolism of Cobimetinib can be decreased when combined with Simeprevir. |
| Simvastatin | The serum concentration of Cobimetinib can be increased when it is combined with Simvastatin. |
| Sincalide | The excretion of Sincalide can be decreased when combined with Cobimetinib. |
| Siponimod | The metabolism of Siponimod can be decreased when combined with Cobimetinib. |
| Sirolimus | The metabolism of Sirolimus can be decreased when combined with Cobimetinib. |
| Sitagliptin | The serum concentration of Cobimetinib can be increased when it is combined with Sitagliptin. |
| Sitaxentan | The metabolism of Cobimetinib can be decreased when combined with Sitaxentan. |
| Sofosbuvir | The serum concentration of Cobimetinib can be increased when it is combined with Sofosbuvir. |
| Somatostatin | The metabolism of Cobimetinib can be decreased when combined with Somatostatin. |
| Somatrogon | The metabolism of Cobimetinib can be increased when combined with Somatrogon. |
| Sonidegib | The metabolism of Sonidegib can be decreased when combined with Cobimetinib. |
| Sorafenib | The serum concentration of Cobimetinib can be increased when it is combined with Sorafenib. |
| Sotagliflozin | The serum concentration of Cobimetinib can be increased when it is combined with Sotagliflozin. |
| Sotorasib | The serum concentration of Cobimetinib can be decreased when it is combined with Sotorasib. |
| St. John’s Wort | The serum concentration of Cobimetinib can be decreased when it is combined with St. John’s Wort. |
| Stiripentol | The metabolism of Cobimetinib can be decreased when combined with Stiripentol. |
| Sulfamethoxazole | The metabolism of Cobimetinib can be decreased when combined with Sulfamethoxazole. |
| Sulfinpyrazone | The metabolism of Cobimetinib can be increased when combined with Sulfinpyrazone. |
| Sunitinib | The metabolism of Sunitinib can be decreased when combined with Cobimetinib. |
| Suvorexant | The serum concentration of Cobimetinib can be increased when it is combined with Suvorexant. |
| Tacrolimus | The serum concentration of Cobimetinib can be increased when it is combined with Tacrolimus. |
| Talazoparib | The serum concentration of Talazoparib can be increased when it is combined with Cobimetinib. |
| Tamoxifen | The serum concentration of Cobimetinib can be increased when it is combined with Tamoxifen. |
| Tasimelteon | The metabolism of Cobimetinib can be decreased when combined with Tasimelteon. |
| Taurocholic acid | The excretion of Taurocholic acid can be decreased when combined with Cobimetinib. |
| Tazemetostat | The metabolism of Cobimetinib can be decreased when combined with Tazemetostat. |
| Technetium | The excretion of Technetium Tc-99m mebrofenin can be decreased when combined with Cobimetinib. |
| Technetium | The serum concentration of Cobimetinib can be increased when it is combined with Technetium Tc-99m sestamibi. |
| Tecovirimat | The metabolism of Cobimetinib can be increased when combined with Tecovirimat. |
| Tegaserod | The serum concentration of Cobimetinib can be increased when it is combined with Tegaserod. |
| Telaprevir | The serum concentration of Cobimetinib can be increased when it is combined with Telaprevir. |
| Telithromycin | The serum concentration of Cobimetinib can be increased when it is combined with Telithromycin. |
| Telotristat ethyl | The serum concentration of Cobimetinib can be decreased when it is combined with Telotristat ethyl. |
| Temsirolimus | The serum concentration of Cobimetinib can be increased when it is combined with Temsirolimus. |
| Teniposide | The metabolism of Cobimetinib can be decreased when combined with Teniposide. |
| Tenofovir | The metabolism of Cobimetinib can be decreased when combined with Tenofovir alafenamide. |
| Tepotinib | The serum concentration of Cobimetinib can be increased when it is combined with Tepotinib. |
| Terbinafine | The metabolism of Cobimetinib can be increased when combined with Terbinafine. |
| Terfenadine | The serum concentration of Cobimetinib can be increased when it is combined with Terfenadine. |
| Testosterone | The metabolism of Cobimetinib can be increased when combined with Testosterone. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Tetracaine. |
| Tetracycline | The metabolism of Cobimetinib can be decreased when combined with Tetracycline. |
| Tezacaftor | The serum concentration of Cobimetinib can be increased when it is combined with Tezacaftor. |
| Theophylline | The metabolism of Theophylline can be decreased when combined with Cobimetinib. |
| Thiamylal | The metabolism of Cobimetinib can be increased when combined with Thiamylal. |
| Thiotepa | The metabolism of Thiotepa can be decreased when combined with Cobimetinib. |
| Ticagrelor | The serum concentration of Cobimetinib can be increased when it is combined with Ticagrelor. |
| Tipranavir | The serum concentration of Cobimetinib can be increased when it is combined with Tipranavir. |
| Tivozanib | The serum concentration of Cobimetinib can be increased when it is combined with Tivozanib. |
| Tocilizumab | The metabolism of Cobimetinib can be increased when combined with Tocilizumab. |
| Tolvaptan | The metabolism of Tolvaptan can be decreased when combined with Cobimetinib. |
| Topiramate | The metabolism of Cobimetinib can be increased when combined with Topiramate. |
| Topotecan | The serum concentration of Topotecan can be increased when it is combined with Cobimetinib. |
| Toremifene | The serum concentration of Cobimetinib can be increased when it is combined with Toremifene. |
| Trabectedin | The metabolism of Trabectedin can be decreased when combined with Cobimetinib. |
| Trastuzumab | The metabolism of Trastuzumab emtansine can be decreased when combined with Cobimetinib. |
| Trazodone | The serum concentration of Cobimetinib can be decreased when it is combined with Trazodone. |
| Triamcinolone | The metabolism of Cobimetinib can be increased when combined with Triamcinolone. |
| Triclabendazole | The metabolism of Cobimetinib can be decreased when combined with Triclabendazole. |
| Trilaciclib | The serum concentration of Cobimetinib can be increased when it is combined with Trilaciclib. |
| Trimipramine | The serum concentration of Trimipramine can be increased when it is combined with Cobimetinib. |
| Troglitazone | The metabolism of Cobimetinib can be increased when combined with Troglitazone. |
| Troleandomycin | The serum concentration of Cobimetinib can be increased when it is combined with Troleandomycin. |
| Tucatinib | Tucatinib may decrease the excretion rate of Cobimetinib which could result in a higher serum level. |
| Ubrogepant | The serum concentration of Cobimetinib can be increased when it is combined with Ubrogepant. |
| Umbralisib | The serum concentration of Cobimetinib can be increased when it is combined with Umbralisib. |
| Umeclidinium | The serum concentration of Cobimetinib can be increased when it is combined with Umeclidinium. |
| Valproic acid | The metabolism of Cobimetinib can be decreased when combined with Valproic acid. |
| Valsartan | The excretion of Valsartan can be decreased when combined with Cobimetinib. |
| Vandetanib | The serum concentration of Cobimetinib can be increased when it is combined with Vandetanib. |
| Vardenafil | The serum concentration of Cobimetinib can be increased when it is combined with Vardenafil. |
| Velpatasvir | The serum concentration of Cobimetinib can be increased when it is combined with Velpatasvir. |
| Vemurafenib | The serum concentration of Cobimetinib can be increased when it is combined with Vemurafenib. |
| Venetoclax | The metabolism of Cobimetinib can be decreased when combined with Venetoclax. |
| Verapamil | The metabolism of Cobimetinib can be decreased when combined with Verapamil. |
| Viloxazine | The metabolism of Cobimetinib can be decreased when combined with Viloxazine. |
| Vinblastine | The metabolism of Cobimetinib can be increased when combined with Vinblastine. |
| Vincristine | The metabolism of Vincristine can be decreased when combined with Cobimetinib. |
| Vindesine | The metabolism of Vindesine can be decreased when combined with Cobimetinib. |
| Vinflunine | The metabolism of Vinflunine can be decreased when combined with Cobimetinib. |
| Vinorelbine | The metabolism of Vinorelbine can be decreased when combined with Cobimetinib. |
| Vitamin E | The metabolism of Cobimetinib can be increased when combined with Vitamin E. |
| Voclosporin | The serum concentration of Cobimetinib can be increased when it is combined with Voclosporin. |
| Vorapaxar | The serum concentration of Cobimetinib can be increased when it is combined with Vorapaxar. |
| Voriconazole | The metabolism of Cobimetinib can be decreased when combined with Voriconazole. |
| Voxelotor | The serum concentration of Cobimetinib can be increased when it is combined with Voxelotor. |
| Voxilaprevir | The serum concentration of Cobimetinib can be increased when it is combined with Voxilaprevir. |
| Warfarin | The metabolism of Cobimetinib can be increased when combined with Warfarin. |
| Zafirlukast | The metabolism of Cobimetinib can be decreased when combined with Zafirlukast. |
| Zanubrutinib | The metabolism of Zanubrutinib can be decreased when combined with Cobimetinib. |
| Zimelidine | The metabolism of Cobimetinib can be decreased when combined with Zimelidine. |
| Ziprasidone | The metabolism of Cobimetinib can be decreased when combined with Ziprasidone. |
Drug-Food Interactions
- Avoid grapefruit products. Grapefruit inhibits the metabolism of cobimetinib through the CYP3A4 pathway and, therefore, may increase serum levels of cobimetinib.
- Avoid St. John’s Wort. This herb induces CYP3A4 metabolism, which may reduce serum levels of cobimetinib.
- Take with or without food. Cobimetinib bioavailability is unaffected by food.
Pregnancy and Lactation
US FDA pregnancy category: Not assigned.
Pregnancy
The proposed labeling states that cobimetinib can cause fetal harm when administered to a pregnant woman based on findings in animal studies, and lists cobimetinib under the pregnancy category. It is not known whether cobimetinib is excreted in human milk.
Lactation
No information is available on the clinical use of cobimetinib during breastfeeding. Because cobimetinib is 90% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 44 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during cobimetinib therapy and for 2 weeks after the last dose.
How should this medicine be used?
Cobimetinib comes as a tablet to take by mouth with or without food. It is usually taken once daily for the first 21 days of a 28-day cycle. Take cobimetinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take cobimetinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
If you vomit after taking cobimetinib do not take another dose. Continue your regular dosing schedule.
Your doctor may decrease your dose of cobimetinib or permanently or temporarily stop your treatment. This depends on how well the medication works for you and the side effects you experience. Be sure to tell your doctor how you are feeling during your treatment with cobimetinib.
Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.
What special precautions should I follow?
Before taking cobimetinib,
- tell your doctor and pharmacist if you are allergic to cobimetinib, any other medications, or any of the ingredients in cobimetinib tablets. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: anticoagulants (blood thinners) such as warfarin (Coumadin, Jantoven), carbamazepine (Carbatrol, Epitol, Tegretol), ciprofloxacin (Cipro), clarithromycin (Biaxin, in Prevpac), efavirenz (Sustiva, in Atripla), erythromycin (E.E.S., E-Mycin, Erythrocin), indinavir (Crixivan), itraconazole (Onmel, Sporanox), ketoconazole (Extina, Ketozole, Nizoral), nefazodone, nelfinavir (Viracept), phenytoin (Dilantin, Phenytek), rifampin (Rifadin, Rimactane, in Rifamate, in Rifater), and ritonavir (Norvir, in Kaletra, in Viekira Pak). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with cobimetinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
- tell your doctor what herbal products you are taking, especially St. John’s Wort. Do not take St. John’s Wort while you are taking cobimetinib.
- tell your doctor if you have or have ever had have skin conditions other than melanoma; bleeding problems; vision problems; any condition that affects your muscles; or heart or liver disease.
- you should know that cobimetinib may decrease fertility in men and women. However, you should not assume that you or your partner cannot become pregnant. Tell your doctor if you are pregnant or plan to become pregnant. Use a reliable method of birth control to prevent pregnancy during your treatment and for 2 weeks after you stop taking cobimetinib. Talk to your doctor about birth control methods that will work for you. If you become pregnant while taking cobimetinib, call your doctor immediately. Cobimetinib may harm the fetus.
- tell your doctor if you are breastfeeding. You should not breastfeed while taking cobimetinib and for 2 weeks after your last dose.
- plan to avoid unnecessary or prolonged exposure to sunlight and to wear protective clothing, sunglasses, lip balm and sunscreen (SPF 30 or higher). Cobimetinib may make your skin sensitive to sunlight.
References
